For the Inventor, By the Inventor

Enter assignee name

Plan-les-Ouates, Switzerland

Geneuro Sa

USPTO Granted Patents = 9

% Expired Patents = 11.1

EPO Patents = 6

Forward Citations = 8

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Herve Perron (6 out of 32 patents)

Alois Bernhardt Lang (5 out of 5 patents)

Corinne Bernard (4 out of 4 patents)

4. Jean-Baptiste Bertrand (4 out of 4 patents)

5. Hervé Perron (3 out of 6 patents)

6. Julie Medina (3 out of 4 patents)

7. Alexandra Madeira (3 out of 3 patents)

8. Raphaël Faucard (3 out of 3 patents)

9. Joseph Perry Steiner (2 out of 4 patents)

10. Wenxue Li (2 out of 2 patents)

11. Avindra Nath (2 out of 8 patents)

12. Reza Firouzi (2 out of 2 patents)

13. Patrick Küry (2 out of 6 patents)

14. Julie Joanou (2 out of 2 patents)

15. Myoung-Hwa Lee (1 out of 1 patent)

9 patents: Sort by Forward Citations

1. 10981977 - Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis (2021-04-20),

2. 10894820 - Antiretroviral drug targeting human endogenous retrovirus (2021-01-19),

3. 10752675 - Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein (2020-08-25),

4. 10723787 - Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody (2020-07-28),

5. 10059758 - Therapeutic use of specific ligand in MSRV associated diseases (2018-08-28),

6. 9840550 - Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein (2017-12-12),

7. 9815888 - Therapeutic use of specific ligand in MSRV associated diseases (2017-11-14),

8. 9550824 - Therapeutic use of specific ligand in MSRV associated diseases (2017-01-24),

9. 8715656 - Therapeutic use of specific ligand in MSRV associated diseases (2014-05-06),

Company Overview

Geneuro Sa is a biopharmaceutical company focused on the development of innovative treatments for neurological and autoimmune diseases. The company's lead product candidate, Temelimab, is in clinical development for the treatment of multiple sclerosis and other autoimmune disorders. Geneuro Sa is committed to advancing novel therapies that address unmet medical needs and improve the lives of patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#9 in Plan-les-Ouates

#1,128 in Switzerland

Plan-les-Ouates, Switzerland

Geneuro Sa

Forward Citations = 8

19 inventors:

Herve Perron (6 out of 32 patents)

Alois Bernhardt Lang (5 out of 5 patents)

Corinne Bernard (4 out of 4 patents)

4. Jean-Baptiste Bertrand (4 out of 4 patents)

5. Hervé Perron (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Geneuro Sa. Retrieved from https://idiyas.com/company/geneuro-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…